david meyer, phd “welcome remarks & introduction to la biomed”
Post on 08-May-2015
363 Views
Preview:
DESCRIPTION
TRANSCRIPT
Statistics:
• Independent/Not-for-profit [501(c)(3)] • 650-1000 research projects • ~100 Investigators - MDs & PhDs
– 75% are LA County Employees (Harbor-UCLA)
• 950+ employees (700 on campus)
Missions:
Biomedical Research Training and Education Community Service
Relationships
Clinical Care Teaching Research
Academic Medical Center
Relationships
Clinical Care Teaching Research
Harbor-UCLA Medical Center UCLA School of Medicine
LA BioMed
LA BioMed Paradigm What we see in the clinic is what we study in the lab.
Our discoveries are rapidly and efficiently protected and developed commercially
By doing so, LA BioMed IP arrives in the clinic in less time.
LA BioMed Highlights 1960’s-Present Paramedic Training Program Nurse-Practitioner Training Program Serum Cholesterol Test Tay-Sachs Blood Test 170,00 Live Births through Ovum Transfer Synthetic Lung Surfactants Anti-microbial eye drops COPD Rehab Therapy Vaccines against Hospital-acquired Infections Treatment for Sickle Cell Disease Male Birth Control Gel Melanoma Vaccine
On the Cutting Edge…
Licensing of LA BioMed IP
2007 2005
2004 2001
2011: PulSentry ImmunoTx 2012: BioAIM SyneuRx
Submental Fat
Treatment For Submental Fat
Michael Kolodney Now in Phase III Clinical Trials
IPO October 2012
Sickle Cell Disease
Red Blood Cells
Yutaka Niihara
Novel Inexpensive Therapy for Sickle Cell Disease
In Phase III Clinical Trials
Nosocomial = Hospital Acquired
Staphylococcus aureus
Candida albicans 60% Lethality
Infections
6th Leading Cause of Death
1. More invasive procedures 2. Antibiotic Resistance 3. No ROI
Vaccines against Nosocomial Infections
Jack Edwards
Phase II Clinical Trials Starting Soon
Christina Wang, MD
LA BioMed Paradigm What we see in the clinic is what we study in the lab.
Our discoveries are rapidly and efficiently protected and developed commercially
By doing so, LA BioMed IP arrives in the clinic in less time.
top related